G5172
GW4064
≥97% (HPLC), farnesoid X receptor agonist, powder
别名:
3-（2,6-二氯苯基）-4-（3′-羧基-2-氯代二苯乙烯-4-基）氧甲基-5-异丙基异恶唑
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C28H22Cl3NO4
化学文摘社编号:
分子量:
542.84
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.32
MDL number:
产品名称
GW4064, ≥97% (HPLC)
SMILES string
CC(C)c1onc(c1COc2ccc(\C=C\c3cccc(c3)C(O)=O)c(Cl)c2)-c4c(Cl)cccc4Cl
InChI
1S/C28H22Cl3NO4/c1-16(2)27-21(26(32-36-27)25-22(29)7-4-8-23(25)30)15-35-20-12-11-18(24(31)14-20)10-9-17-5-3-6-19(13-17)28(33)34/h3-14,16H,15H2,1-2H3,(H,33,34)/b10-9+
InChI key
BYTNEISLBIENSA-MDZDMXLPSA-N
assay
≥97% (HPLC)
form
powder
storage condition
desiccated
color
white
solubility
DMSO: 10 mg/mL, clear
storage temp.
2-8°C
Quality Level
相关类别
General description
GW4064是合成异恶唑，用于揭示类法尼醇X受体（FXR）的细胞结构和生理功能。是雌激素受体相关受体（ERR）激动剂。
Application
GW4064用于：
- 研究其保护小鼠肝脏免受脂多糖（LPS）诱导炎症和细胞凋亡影响的能力
- 研究其抑制脂多糖（LPS）引起回肠粘膜损伤的能力
- 处理回肠外植体
Biochem/physiol Actions
GW4064 是一种 FXR 激动剂。
GW4064 是一种 FXR 激动剂。GW4064 是孤儿核受体 FXR 的强效 (EC50 = 15 nM) 非甾体激动剂。它对其他核受体（包括高达1 mM 的 RAR）没有活性，是研究 FXR 参与多种生物活动的重要工具。
Features and Benefits
该化合物由GlaxoSmithKline开发。要浏览其他药物开发化合物和批准的药物/候选药物列表，单击此处。
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Chronic 4 - Eye Irrit. 2
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Farnesoid X receptor agonist GW4064 ameliorates lipopolysaccharide-induced ileocolitis through TLR4/MyD88 pathway related mitochondrial dysfunction in mice
Liu HM, et al.
Biochemical and Biophysical Research Communications, 490(3), 841-848 (2017)
Xiang Jiang et al.
Journal of autoimmunity, 90, 64-75 (2018-02-13)
Mucosal-associated invariant T (MAIT) cells are novel innate-like T cells constituting a significant proportion of circulating and hepatic T cells. Herein, we extensively examine the phenotypical and functional alterations of MAIT cells and their regulation in a cohort of 56
Synthetic FXR Agonist GW4064 Is a Modulator of Multiple G Protein-Coupled Receptors
Singh N, et al.
Molecular Endocrinology, 28(5), 659-673 (2014)
Mingyi Liu et al.
Frontiers in pharmacology, 11, 375-375 (2020-04-16)
Berberine, a quinoline alkaloid, can be used in combination with statins to enhance hypolipidemic effects and reduce the dose and side effects of statins. The hypolipidemic effects of statins in the liver are mainly regulated by organic anion transporting polypeptides
Esther M Verhaag et al.
PloS one, 11(3), e0149782-e0149782 (2016-03-08)
Cholestasis is characterized by accumulation of bile acids and inflammation, causing hepatocellular damage. Still, liver damage markers are highest in acute cholestasis and drop when this condition becomes chronic, indicating that hepatocytes adapt towards the hostile environment. This may be
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持